Senti Biosciences Holdings (SNTI) Receivables (2022 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Receivables of $500000.0 for Q4 2025, down 28.57% year-over-year from $700000.0 in Q4 2024, and down 68.69% quarter-over-quarter from $1.6 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Receivables (2022 - 2025) Analysis & Trends
Senti Biosciences Holdings' Receivables history runs 4 years deep, the most recent figure standing at $500000.0 for Q4 2025.
- In Q4 2025, Receivables fell 28.57% year-over-year to $500000.0; the TTM figure through Dec 2025 stood at $500000.0 (down 28.57% YoY), while the FY2025 annual figure was $500000.0, down 28.57% from the prior year.
- Receivables for Q4 2025 stood at $500000.0, down from $1.6 million in the prior quarter.
- The five-year high for Receivables was $17.8 million in Q1 2024, with the low at $500000.0 in Q4 2025.
- The 4-year median for Receivables is $900000.0 (2024), against an average of $3.5 million.
- Peak annual rise in Receivables reached 2156.26% in 2024, while the deepest fall reached 96.02% in 2024.
- Senti Biosciences Holdings' Receivables stood at $846000.0 in 2022, then surged by 1979.43% to $17.6 million in 2023, then plunged by 96.02% to $700000.0 in 2024, then retreated by 28.57% to $500000.0 in 2025.
- Business Quant data shows SNTI's Receivables at $500000.0 in Q4 2025, $1.6 million in Q3 2025, and $3.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Senti Biosciences Holdings | 11.83 Mn | 11.83 Mn | - | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 3.52 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 17.85 Mn |
| Dec 31, 2023 | 17.59 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 567,000.00 |
| Mar 31, 2023 | 791,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 573,000.00 |